EGFR Positive Non-small Cell Lung Cancer
Showing 1 - 15 of 15
NSCLC Stage III, EGFR Positive NSCLC, Non-squamous Non-small-cell Lung Cancer Trial in Korea, Republic of (Lazertinib)
Recruiting
- Non-small Cell Lung Cancer Stage III
- +2 more
-
Busan, Korea, Republic of
- +9 more
Jun 30, 2022
NSCLC, EGFR Positive NSCLC, Oligoprogression Trial in München (Osimertinib, Radiotherapy)
Recruiting
- NSCLC
- +2 more
- Osimertinib
- Radiotherapy
-
München, GermanyLMU Klinikum der Universität München
May 17, 2022
Stage IV NSCLC, Targeted Therapy, Nonsmall Cell Lung Cancer Trial in Boston (POISE)
Not yet recruiting
- Stage IV Non-small Cell Lung Cancer
- +7 more
- POISE
-
Boston, MassachusettsMassachusetts General Hospital
Apr 13, 2022
EGFR Positive NSCLC Trial in Goyang-Si (Erlotinib plus Bevacizumab, Erlotinib)
Active, not recruiting
- EGFR Positive Non-small Cell Lung Cancer
- Erlotinib plus Bevacizumab
- Erlotinib
-
Goyang-Si, Gyeonggi-do, Korea, Republic ofNational Cancer Center
Apr 4, 2022
EGFR Positive NSCLC Trial in China (APG-1252, Osimertinib Mesylate Tablets)
Recruiting
- EGFR Positive Non-small Cell Lung Cancer
- APG-1252
- Osimertinib Mesylate Tablets
-
Guangzhou, Guangdong, China
- +3 more
Oct 27, 2021
Osimertinib for Advanced EGFR-positive NSCLC Patients
Recruiting
- EGFR Positive Non-small Cell Lung Cancer
- Non Small Cell Lung Cancer
-
Singapore, SingaporeNational University Hospital
Aug 31, 2021
EGFR Positive NSCLC Trial in Korea, Republic of (EGFR)
Active, not recruiting
- EGFR Positive Non-small Cell Lung Cancer
-
Anyang, Gyeonggi-do, Korea, Republic of
- +7 more
Jul 13, 2021
EGFR Positive NSCLC, Brain Metastases Trial in Hangzhou (Almonertinib)
Not yet recruiting
- EGFR Positive Non-small Cell Lung Cancer
- Brain Metastases
-
Hangzhou, Zhejiang, ChinaHangzhou Cancer Hospital
Nov 19, 2020
Workup at Disease Progression and Implementation of Osimertinib
Unknown status
- EGFR Positive Non-small Cell Lung Cancer
-
Heidelberg, GermanyThoraxklinik-Heidelberg gGmbH - Universitätsklinikum Heidelberg
Mar 9, 2020
EGFR Positive NSCLC, Adenocarcinoma Trial in Beijing (Icotinib, Placebo)
Unknown status
- EGFR Positive Non-small Cell Lung Cancer
- Adenocarcinoma
- Icotinib
- Placebo
-
Beijing, Beijing, China
- +10 more
Jul 12, 2018
Lung Adenocarcinoma, EGFR Positive NSCLC Trial (EGFR-TKI, Thoracic Hypofractionated Radiotherapy)
Unknown status
- Lung Adenocarcinoma
- EGFR Positive Non-small Cell Lung Cancer
- EGFR-TKI
- Thoracic Hypofractionated Radiotherapy
- (no location specified)
May 26, 2016
EGFR Positive NSCLC, Adenocarcinoma Trial in China (Sequential Icotinib Plus Chemotherapy, Icotinib)
Unknown status
- EGFR Positive Non-small Cell Lung Cancer
- Adenocarcinoma
- Sequential Icotinib Plus Chemotherapy
- Icotinib
-
Lanzhou, Gansu, China
- +30 more
Apr 27, 2015
EGFR Positive NSCLC, Adenocarcinoma Trial in NanNing (Sequential and maintenance icotinib, Maintenance icotinib)
Unknown status
- EGFR Positive Non-small Cell Lung Cancer
- Adenocarcinoma
- Sequential and maintenance icotinib
- Maintenance icotinib
-
NanNing, Guangxi, ChinaFirst Affiliated Hospital of Guangxi Medical University
Jul 17, 2014